Redirection of T cells with a first fully humanized bispecific CD33–CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

(2012) R. B. Walter et al.   BLOOD

Recent advances in acute myeloid leukemia stem cell biology

(2012) S. J. Horton et al.   HAEMATOLOGICA

Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells

(2012) A. Feldmann et al.   JOURNAL OF IMMUNOLOGY

Retargeting of Human Regulatory T Cells by Single-Chain Bispecific Antibodies

(2011) S. Koristka et al.   JOURNAL OF IMMUNOLOGY

Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells

(2011) S Stamova et al.   LEUKEMIA

Unexpected recombinations in single chain bispecific anti-CD3–anti-CD33 antibodies can be avoided by a novel linker module

(2011) Slava Stamova et al.   MOLECULAR IMMUNOLOGY

Current and emerging therapies for acute myeloid leukemia

(2010) Tadeusz Robak et al.   CLINICAL THERAPEUTICS

Hematopoietic stem cells in co-culture with mesenchymal stromal cells - modeling the niche compartments in vitro

(2010) D. Jing et al.   HAEMATOLOGICA